Literature DB >> 1617858

Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

F G Larsen1, F Nielsen-Kudsk, P Jakobsen, K Weismann, K Kragballe.   

Abstract

The retinoids are a class of compounds that includes the natural forms and synthetic analogues of vitamin A. Isotretinoin, often referred to as a first generation retinoid, may be of considerable benefit to patients with severe, recalcitrant acne. Etretinate and acitretin, 2 aromatic compounds representing the second generation, have found their major success in the treatment of psoriasis, particularly in combination with more traditional therapies. Retinoid therapy is associated with a distinctive adverse effect profile typical of hypervitaminosis A; thus, it is especially important that fertile women undergoing retinoid therapy adhere to a contraceptive regimen. These drugs are extensively metabolised and only traces of unchanged drugs are eliminated in urine. The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively. Because of lack of definite correlation between plasma concentration and desired pharmacological effects, in conjunction with the very pronounced inter- and intraindividual variation in systemic availability (15 to 90%) after oral administration of these drugs, initial dosages in individual patients can only be roughly judged on the basis of the general pharmacokinetics of the agents. Later dosage adjustments should be made on the basis of monitoring of both plasma drug (and possible metabolite) concentrations, and the efficacy and tolerability of the drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617858     DOI: 10.2165/00003088-199223010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  88 in total

Review 1.  Relationships between calcium and cyclic nucleotides in cell activation.

Authors:  H Rasmussen; D B Goodman
Journal:  Physiol Rev       Date:  1977-07       Impact factor: 37.312

2.  Isotretinoin--an explanation for its long-term benefit.

Authors:  W J Cunliffe; J F Norris
Journal:  Dermatologica       Date:  1987

3.  Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate.

Authors:  J J DiGiovanna; R K Helfgott; L H Gerber; G L Peck
Journal:  N Engl J Med       Date:  1986-11-06       Impact factor: 91.245

4.  Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.

Authors:  H Gollnick; R Bauer; C Brindley; C E Orfanos; G Plewig; H Wokalek; E Hoting
Journal:  J Am Acad Dermatol       Date:  1988-09       Impact factor: 11.527

5.  Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion.

Authors:  J A Goldstein; A Socha-Szott; R J Thomsen; P E Pochi; A R Shalita; J S Strauss
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

6.  Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase.

Authors:  N J Lowe; R Kaplan; J Breeding
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

7.  Decreased urinary polyamines in patients with psoriasis treated with etretinate.

Authors:  R C Grekin; C N Ellis; N G Goldstein; N A Swanson; T F Anderson; E A Duell; J J Voorhees
Journal:  J Invest Dermatol       Date:  1983-03       Impact factor: 8.551

8.  A rapid and simple test system for the evaluation of the inhibitory activity of retinoids on induced ornithine decarboxylase activity in the hairless rat epidermis.

Authors:  M Bouclier; B Shroot; J Eustache; C N Hensby
Journal:  J Pharmacol Methods       Date:  1986-09

9.  Lipid and teratogenic effects of retinoids.

Authors:  A R Shalita
Journal:  J Am Acad Dermatol       Date:  1988-07       Impact factor: 11.527

10.  Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne.

Authors:  D A Norris; R Osborn; W Robinson; M G Tonnesen
Journal:  J Invest Dermatol       Date:  1987-07       Impact factor: 8.551

View more
  6 in total

Review 1.  Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.

Authors:  D D Tang-Liu; R M Matsumoto; J I Usansky
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

2.  Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells.

Authors:  J Gille; L L Paxton; T J Lawley; S W Caughman; R A Swerlick
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 4.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.

Authors:  Zhiling Yu; Dale Yu; Patricia S Walker; Diane D-S Tang-Liu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Retinoids as a potential treatment for experimental puromycin-induced nephrosis.

Authors:  V Moreno-Manzano; F Mampaso; J C Sepúlveda-Muñoz; M Alique; S Chen; F N Ziyadeh; M C Iglesias-de la Cruz; J Rodríguez; E Nieto; J M Orellana; P Reyes; I Arribas; Q Xu; M Kitamura; F J Lucio Cazana
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.